JP2016502515A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502515A5
JP2016502515A5 JP2015540158A JP2015540158A JP2016502515A5 JP 2016502515 A5 JP2016502515 A5 JP 2016502515A5 JP 2015540158 A JP2015540158 A JP 2015540158A JP 2015540158 A JP2015540158 A JP 2015540158A JP 2016502515 A5 JP2016502515 A5 JP 2016502515A5
Authority
JP
Japan
Prior art keywords
seq
antigen
sequence
identity
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540158A
Other languages
English (en)
Japanese (ja)
Other versions
JP6445444B2 (ja
JP2016502515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/073036 external-priority patent/WO2014068139A1/en
Publication of JP2016502515A publication Critical patent/JP2016502515A/ja
Publication of JP2016502515A5 publication Critical patent/JP2016502515A5/ja
Application granted granted Critical
Publication of JP6445444B2 publication Critical patent/JP6445444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540158A 2012-11-05 2013-11-05 新規抗原結合タンパク質および癌の治療のためのアドレッシング産物(addressingproduct)としてのそれらの使用 Active JP6445444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12290383.4 2012-11-05
EP12290383 2012-11-05
PCT/EP2013/073036 WO2014068139A1 (en) 2012-11-05 2013-11-05 Novel antigen binding proteins and their use as addressing product for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016502515A JP2016502515A (ja) 2016-01-28
JP2016502515A5 true JP2016502515A5 (OSRAM) 2016-12-22
JP6445444B2 JP6445444B2 (ja) 2018-12-26

Family

ID=47278721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540158A Active JP6445444B2 (ja) 2012-11-05 2013-11-05 新規抗原結合タンパク質および癌の治療のためのアドレッシング産物(addressingproduct)としてのそれらの使用

Country Status (14)

Country Link
US (1) US9624308B2 (OSRAM)
EP (1) EP2914630B1 (OSRAM)
JP (1) JP6445444B2 (OSRAM)
KR (1) KR102167228B1 (OSRAM)
CN (1) CN104955842B (OSRAM)
AR (1) AR093357A1 (OSRAM)
BR (1) BR112015010046B1 (OSRAM)
CA (1) CA2890265C (OSRAM)
DK (1) DK2914630T3 (OSRAM)
ES (1) ES2871815T3 (OSRAM)
HU (1) HUE054115T2 (OSRAM)
PL (1) PL2914630T3 (OSRAM)
TW (1) TWI609887B (OSRAM)
WO (1) WO2014068139A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518382A (ja) * 2013-04-26 2016-06-23 ピエール、ファーブル、メディカマン Axl抗体薬物複合体および癌の治療のためのその使用
ES2774428T3 (es) 2014-07-11 2020-07-21 Genmab As Anticuerpos que se unen a AXL
ES2764299T3 (es) * 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
JP6931609B2 (ja) * 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Axlアンタゴニスト抗体
JP6913030B2 (ja) * 2015-05-18 2021-08-04 アジェンシス,インコーポレイテッド Axlタンパク質に結合する抗体
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
LT3319993T (lt) * 2015-07-10 2020-05-11 Genmab A/S Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CN110483639A (zh) 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
US20230140976A1 (en) * 2020-03-30 2023-05-11 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
JP2023521753A (ja) 2020-04-08 2023-05-25 ベルゲンビオ アーエスアー 抗ウイルス療法
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
WO2022212790A1 (en) * 2021-03-31 2022-10-06 President And Fellows Of Harvard College Methods of modulating hair growth

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR20120035145A (ko) 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 axl 항체
MX2011012136A (es) * 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US20110302970A1 (en) 2010-06-15 2011-12-15 Keybrid, Inc. Key - Key holder Combination
WO2011159980A1 (en) * 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2016502515A5 (OSRAM)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2014502955A5 (OSRAM)
JP2020503891A5 (OSRAM)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
JP2017506217A5 (OSRAM)
JP2018508509A5 (OSRAM)
JP2013520996A5 (OSRAM)
JP2020500538A5 (OSRAM)
JP2018527919A5 (OSRAM)
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP2014205674A5 (OSRAM)
JP2015522252A5 (OSRAM)
JP2017500018A5 (OSRAM)
RU2014120629A (ru) Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
JP2015534577A5 (OSRAM)
JP2015502138A5 (OSRAM)
JP2012254092A5 (OSRAM)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2017113019A5 (OSRAM)
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
JP2016116527A5 (OSRAM)